Axiommax Oncology Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 22-06-2024
- Paid Up Capital ₹ 0.10 M
as on 22-06-2024
- Company Age 8 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 83.80%
(FY 2022)
- Profit 6.99%
(FY 2022)
- Ebitda -238.48%
(FY 2022)
- Net Worth -27.21%
(FY 2022)
- Total Assets 67.45%
(FY 2022)
About Axiommax Oncology
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Ashokkumar Jain and Uttamchand Jain serve as directors at the Company.
- CIN/LLPIN
U24110MH2016PTC284390
- Company No.
284390
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Aug 2016
- Date of AGM
27 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Axiommax Oncology?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ashokkumar Jain  | Director | 03-Aug-2016 | Current |
| Uttamchand Jain | Director | 03-Aug-2016 | Current |
Financial Performance and Corporate Structure Insights of Axiommax Oncology.
Axiommax Oncology Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 83.8% increase. The company also saw a slight improvement in profitability, with a 6.99% increase in profit. The company's net worth observed a substantial decline by a decrease of 27.21%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Axiommax Oncology?
In 2019, Axiommax Oncology had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Neon Laboratories LimitedActive 42 years 6 monthsAshokkumar Jain and Uttamchand Jain are mutual person
Vhb Pharmaceuticals Private LimitedActive 29 years 1 monthAshokkumar Jain and Uttamchand Jain are mutual person
- Vhb Medi Sciences LimitedActive 17 years 3 months
Ashokkumar Jain and Uttamchand Jain are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Axiommax Oncology?
Axiommax Oncology has a workforce of 31 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Axiommax Oncology, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Axiommax Oncology's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
